Sympathoinhibitory signals from the gut and obesity-related hypertension

被引:0
|
作者
Daniela M. Sartor
机构
[1] University of Melbourne,Clinical Pharmacology and Therapeutics Unit, Department of Medicine
[2] Austin Health,undefined
来源
关键词
Sympathetic nervous system; Cholecystokinin; Leptin; Obesity; Hypertension; Cardiovascular;
D O I
暂无
中图分类号
学科分类号
摘要
Several gastrointestinal hormones are commonly associated with satiety and digestion, but recent studies suggest they are also involved in regulating hemodynamic demand after a meal. These hormones released from the gut postprandially play a role in short-term cardiovascular regulation via a vagally mediated sympathoinhibitory reflex mechanism, similar to that of the arterial baroreflex. It has been hypothesized that activation of this reflex may promote greater blood flow to the splanchnic and renal vasculature that have increased haemodynamic demand after a meal, while simultaneously inducing vasoconstriction to the skeletomuscular vasculature where it is needed less. Together, the renal and splanchnic circulations can command over 50 % of cardiac output so that the role of gut hormones in controlling sympathetic vasomotor tone to these vascular beds may be more important in cardiovascular regulation than previously thought. The exact aetiology of obesity-related hypertension remains to be determined and is likely to be multifactorial, although the involvement of gut hormone signalling in the development of this disease has not previously been considered. Diets rich in fats and increased food intake are amongst the leading causes of obesity and precipitate significant changes such as inflammation in the gastrointestinal environment that can lead to blunted vagal afferent signalling. In obesity, these changes may disrupt sympathoinhibitory mechanisms and subsequently lead to increased vascular resistance in the gastrointestinal and renal vascular beds, contributing to the development of hypertension.
引用
收藏
页码:33 / 39
页数:6
相关论文
共 50 条
  • [31] Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders
    Sankararaman S.
    Noriega K.
    Velayuthan S.
    Sferra T.
    Martindale R.
    [J]. Current Gastroenterology Reports, 2023, 25 (2) : 31 - 44
  • [32] Obesity-related hypertension: possible pathophysiological mechanisms
    Vaneckova, Ivana
    Maletinska, Lenka
    Behuliak, Michal
    Nagelova, Veronika
    Zicha, Josef
    Kunes, Jaroslav
    [J]. JOURNAL OF ENDOCRINOLOGY, 2014, 223 (03) : R63 - R78
  • [33] Neural mechanisms in human obesity-related hypertension
    Rumantir, MS
    Vaz, M
    Jennings, GL
    Collier, G
    Kaye, DM
    Seals, DR
    Wiesner, GH
    Brunner-La Rocca, HP
    Esler, MD
    [J]. JOURNAL OF HYPERTENSION, 1999, 17 (08) : 1125 - 1133
  • [34] Adrenergic and reflex abnormalities in obesity-related hypertension
    Grassi, G
    Seravalle, G
    Dell'Oro, R
    Turri, C
    Bolla, GB
    Mancia, G
    [J]. HYPERTENSION, 2000, 36 (04) : 538 - 542
  • [35] Neural mechanisms and management of obesity-related hypertension
    Esler M.D.
    Eikelis N.
    Lambert E.
    Straznicky N.
    [J]. Current Cardiology Reports, 2008, 10 (6) : 456 - 463
  • [36] Treatment of Obesity-Related Hypertension in Children and Adolescents
    Halbach, Susan M.
    Flynn, Joseph
    [J]. CURRENT HYPERTENSION REPORTS, 2013, 15 (03) : 224 - 231
  • [37] Cardiac transcriptome analysis in obesity-related hypertension
    Philip-Couderc, P
    Smih, F
    Pelat, M
    Vidal, C
    Verwaerde, P
    Pathak, A
    Buys, S
    Galinier, M
    Senard, JM
    Rouet, P
    [J]. HYPERTENSION, 2003, 41 (03) : 414 - 421
  • [38] Hydralazine as antihypertensive therapy in obesity-related hypertension
    Carroll, JF
    King, JW
    Cohen, JS
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (03) : 384 - 390
  • [39] Adiponectin replenishment ameliorates obesity-related hypertension
    Ohashi, Koji
    Kihara, Shinji
    Ouchi, Noriyuki
    Kumada, Masahiro
    Fujita, Koichi
    Hiuge, Aki
    Hibuse, Toshiyuki
    Ryo, Miwa
    Nishizawa, Hitoshi
    Maeda, Norikazu
    Maeda, Kazuhisa
    Shibata, Rei
    Walsh, Kenneth
    Funahashi, Tohru
    Shimomura, Iichiro
    [J]. HYPERTENSION, 2006, 47 (06) : 1108 - 1116
  • [40] Hydralazine as antihypertensive therapy in obesity-related hypertension
    J F Carroll
    J W King
    J S Cohen
    [J]. International Journal of Obesity, 2004, 28 : 384 - 390